Molecular Signaling Distinguishes Early ER Positive Breast Cancer Recurrences Despite Adjuvant Tamoxifen.

被引：2
|
作者：
Liu, M. C. [1 ]
Dixon, J. M. [1 ]
Xuan, J. J. [1 ]
Riggins, R. B. [1 ]
Chen, L. [1 ]
Wang, C. [1 ]
Cho, Y. [1 ]
Zhu, Y. [1 ]
Jin, L. [1 ]
Zwart, A. [1 ]
Wang, M. [1 ]
Klimach, U. M. [1 ]
Wang, Y. J. [1 ]
Renshaw, L. [1 ]
Larionov, A. [1 ]
Miller, W. R. [1 ]
Clarke, R. [1 ]
机构：
[1] Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
CANCER RESEARCH | 2011年 / 71卷
关键词：
D O I：
10.1158/0008-5472.SABCS11-S1-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
S1-8
引用
收藏
页数：1
相关论文
共 50 条
  • [31] PTEN protein expression in postmenopausal steroid receptor positive early breast cancer patients treated with adjuvant tamoxifen
    Milovanovic, Z.
    Dzodic, R.
    Susnjar, S.
    Plesinac-Karapandzic, V.
    Juranic, Z.
    Tatic, S.
    JOURNAL OF BUON, 2011, 16 (01): : 46 - 51
  • [32] Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells
    Shreya Banerjee
    Suman Kambhampati
    Inamul Haque
    Sushanta K. Banerjee
    Journal of Cell Communication and Signaling, 2011, 5 : 317 - 324
  • [33] Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen
    Kennecke, Hagen
    McArthur, Heather
    Olivotto, Ivo A.
    Speers, Caroline
    Bajdik, Chris
    Chia, Stephen K.
    Ellard, Susan
    Norris, Brian
    Hayes, Malcolm
    Barnett, Jeff
    Gelmon, Karen A.
    CANCER, 2008, 112 (07) : 1437 - 1444
  • [34] LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
    X Xue
    Y A Yang
    A Zhang
    K-W Fong
    J Kim
    B Song
    S Li
    J C Zhao
    J Yu
    Oncogene, 2016, 35 : 2746 - 2755
  • [35] LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
    Xue, X.
    Yang, Y. A.
    Zhang, A.
    Fong, K-W
    Kim, J.
    Song, B.
    Li, S.
    Zhao, J. C.
    Yu, J.
    ONCOGENE, 2016, 35 (21) : 2746 - 2755
  • [36] Dead end in treating tamoxifen resistant breast cancer? Using FASLODEX to overcome Tamoxifen resistance in ER-positive breast cancer
    Dholakia, C.
    Vareslija, D.
    Purcell, S. P.
    Hill, A.
    Young, L.
    BRITISH JOURNAL OF SURGERY, 2017, 104 : 54 - 54
  • [37] Continued proliferation despite letrozole or tamoxifen in HER2-positive breast cancer
    Nature Clinical Practice Oncology, 2006, 3 (10): : 530 - 531
  • [38] Pomegranate sensitizes Tamoxifen action in ER-α positive breast cancer cells
    Banerjee, Shreya
    Kambhampati, Suman
    Banerjee, Sushanta K.
    Haque, Inamul
    JOURNAL OF CELL COMMUNICATION AND SIGNALING, 2011, 5 (04) : 317 - 324
  • [39] POSITIVE EFFECT OF TAMOXIFEN AS PART OF ADJUVANT CHEMOENDOCRINE THERAPY FOR BREAST-CANCER
    UCHINO, J
    SAMEJIMA, N
    TANABE, T
    HAYASAKA, H
    MITO, M
    HATA, Y
    ASAISHI, K
    SASAKI, M
    OGITA, M
    SAITO, T
    SAITO, I
    HAMADA, T
    KAWAMOTO, K
    YOSHIMOTO, M
    HAMADA, M
    MIYATA, S
    KOSHINO, I
    HASEGAWA, M
    NAKANISHI, M
    ATSUTA, T
    KATAOKA, K
    ISHIZAKI, M
    TAGUCHI, K
    NISHIOKA, H
    TACHIBANA, H
    OHIRA, S
    ASANO, S
    HISHIYAMA, T
    OZAWA, T
    SAITOH, M
    HASHIMOTO, H
    MIYASAKA, S
    MURAMATSU, M
    OKUNO, T
    ABE, S
    FUJISAWA, J
    ITOH, T
    SHIONO, T
    MIURA, T
    TAKAGI, M
    KYUNO, K
    KITAYAMA, S
    KAGAYA, H
    ISOMATSU, T
    TAKAGI, R
    MIYAKAWA, K
    TANAKA, N
    TAKAHASHI, T
    NISHIMURA, A
    HASHIHATA, T
    BRITISH JOURNAL OF CANCER, 1994, 69 (04) : 767 - 771
  • [40] NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
    Kim, Yu Cheon
    Kim, Clara Yuri
    Oh, Ji Hoon
    Kim, Myoung Hee
    CELLS, 2021, 10 (07)
12345